Sibylla Biotech

Sibylla Biotech is a preclinical-stage drug discovery company that uses computer simulations and AI to develop small molecule degraders through a proprietary mechanism called PPI-FIT (Pharmacological Protein Inactivation by Folding Intermediates Targeting). This approach enables the discovery of compounds that induce target protein degradation by interfering with protein folding pathways, applicable across multiple therapeutic areas. The company's pipeline focuses on targets including Cyclin D1 and KRAS for oncology and inflammatory diseases, and it has established drug discovery collaborations with Takeda and Ono Pharmaceutical. Sibylla's Oneiros AI Platform and protein folding simulation capabilities differentiate it in the AI-driven drug discovery landscape. A spin-off of INFN, the University of Trento, and the University of Perugia, the company was selected by Nature as one of the eight best life-science startups globally. Founded in 2017 and headquartered in Trento, Italy, Sibylla has raised approximately $25.2 million in a Series A round backed by investors including Vertis SGR, V-Bio Ventures, Seroba Life Sciences, CDP Venture Capital, and Indaco Venture Partners.

Life Sciences Tech > Research & Development > Drug Discovery > Cheminformatics > Lead Discovery > AI Based,

Oncology > Drugs > Diversified,

Life Sciences Platforms and Tools > Research Assays > Drug Discovery